AstraZeneca’s Imfinzi combination shows promise in phase 3 liver cancer study

2024-01-23

临床结果临床3期ASCO会议免疫疗法上市批准

AstraZeneca’s Imfinzi combination shows promise in phase 3 liver cancer study

Preview

来源: PMLiVE

AstraZeneca (AZ) has shared positive results from a late-stage study evaluating its immunotherapy Imfinzi (durvalumab) in a subset of patients with hepatocellular carcinoma (HCC), the most common type of liver cancer.

The phase 3 EMERALD-1 trial has been comparing Imfinzi plus transarterial chemoembolisation (TACE), followed by Imfinzi with or without Genentech’s Avastin (bevacizumab), until progression against TACE alone in more than 600 patients with unresectable HCC eligible for embolisation.

About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation, a procedure that blocks blood supply to the tumour and can also deliver chemotherapy or radiation therapy directly to the liver.

Despite being the standard of care in this setting, AZ outlined that most patients who receive embolisation experience rapid disease progression or recurrence.

According to the results from EMERALD-1, which were presented at this year’s American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Imfinzi in combination with TACE and Avastin reduced the risk of disease progression or death by 23% compared to TACE alone.

Median progression-free survival (PFS) was 15 months in patients treated with the Imfinzi combination versus 8.2 months with TACE and the PFS benefit was "generally consistent" across key pre-specified subgroups, AZ said.

The company added that the secondary endpoint of time to progression "further supports the clinical benefit" of the Imfinzi combination in this setting, at a median of 22 months versus ten months for TACE. The trial will continue to follow the key secondary endpoint of overall survival.

Susan Galbraith, executive vice president, oncology research and development, AZ, said: "With Imfinzi-based treatment, patients with liver cancer eligible for embolisation lived nearly seven additional months before their disease progressed.

“We are discussing these positive EMERALD-1 data with global regulatory authorities while awaiting the final overall survival results from the trial.”

Imfinzi is already approved in combination with AZ's Imjudo (tremelimumab) in unresectable HCC in the US, EU, Japan and other countries worldwide.

Lead investigator in EMERALD-1, Bruno Sangro, from Clínica Universidad de Navarra in Spain, said: “Adding [Imfinzi] and [Avastin] to TACE reduced the risk of disease progression or death by 23% for patients with liver cancer eligible for embolisation, showing for the first time that combining a systemic treatment with TACE meaningfully improves this clinically relevant outcome in earlier-stage disease.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构